These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 33041828)

  • 21. The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis.
    Zhao H; Wang S; Song C; Zha Y; Li L
    World J Surg Oncol; 2016 Oct; 14(1):261. PubMed ID: 27733166
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MGMT-Positive vs MGMT-Negative Patients With Glioblastoma: Identification of Prognostic Factors and Resection Threshold.
    Katsigiannis S; Grau S; Krischek B; Er K; Pintea B; Goldbrunner R; Stavrinou P
    Neurosurgery; 2021 Mar; 88(4):E323-E329. PubMed ID: 33432978
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The prognostic value of MGMT promoter methylation in Glioblastoma multiforme: a meta-analysis.
    Zhang K; Wang XQ; Zhou B; Zhang L
    Fam Cancer; 2013 Sep; 12(3):449-58. PubMed ID: 23397067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
    Li H; Li J; Cheng G; Zhang J; Li X
    Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
    [TBL] [Abstract][Full Text] [Related]  

  • 25. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
    Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
    Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The utilization of MGMT promoter methylation testing in United States hospitals for glioblastoma and its impact on prognosis.
    Lee A; Youssef I; Osborn VW; Safdieh J; Becker DJ; Schreiber D
    J Clin Neurosci; 2018 May; 51():85-90. PubMed ID: 29483008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
    Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
    Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma.
    Rivera AL; Pelloski CE; Gilbert MR; Colman H; De La Cruz C; Sulman EP; Bekele BN; Aldape KD
    Neuro Oncol; 2010 Feb; 12(2):116-21. PubMed ID: 20150378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation of the quantitative level of MGMT promoter methylation and overall survival in primary diagnosed glioblastomas using the quantitative MethyQESD method.
    von Rosenstiel C; Wiestler B; Haller B; Schmidt-Graf F; Gempt J; Bettstetter M; Rihani L; Wu W; Meyer B; Schlegel J; Liesche-Starnecker F
    J Clin Pathol; 2020 Feb; 73(2):112-115. PubMed ID: 31422371
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors.
    Mellai M; Monzeglio O; Piazzi A; Caldera V; Annovazzi L; Cassoni P; Valente G; Cordera S; Mocellini C; Schiffer D
    J Neurooncol; 2012 May; 107(3):617-31. PubMed ID: 22287028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment patterns and outcomes for patients with newly diagnosed glioblastoma multiforme: a retrospective cohort study.
    Annavarapu S; Gogate A; Pham T; Davies K; Singh P; Robert N
    CNS Oncol; 2021 Sep; 10(3):CNS76. PubMed ID: 34378977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predominance of MGMT promoter methylation among Pakistani glioblastoma patients.
    Muhammad N; Fasih S; Malik B; Hameed S; Loya A; Rashid MU
    Mol Biol Rep; 2024 Mar; 51(1):433. PubMed ID: 38520591
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MGMT gene promoter methylation in pediatric glioblastomas.
    Srivastava A; Jain A; Jha P; Suri V; Sharma MC; Mallick S; Puri T; Gupta DK; Gupta A; Sarkar C
    Childs Nerv Syst; 2010 Nov; 26(11):1613-8. PubMed ID: 20585787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MGMT expression and promoter methylation status may depend on the site of surgical sample collection within glioblastoma: a possible pitfall in stratification of patients?
    Della Puppa A; Persano L; Masi G; Rampazzo E; Sinigaglia A; Pistollato F; Denaro L; Barzon L; Palù G; Basso G; Scienza R; d'Avella D
    J Neurooncol; 2012 Jan; 106(1):33-41. PubMed ID: 21725802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between glioblastoma cell-derived vessels and poor prognosis of the patients.
    Mei X; Chen YS; Zhang QP; Chen FR; Xi SY; Long YK; Zhang J; Cai HP; Ke C; Wang J; Chen ZP
    Cancer Commun (Lond); 2020 May; 40(5):211-221. PubMed ID: 32359215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. O
    Alassiri AH; Alkhaibary A; Al-Sarheed S; Alsufani F; Alharbi M; Alkhani A; Aloraidi A
    Ann Saudi Med; 2019; 39(6):410-416. PubMed ID: 31804140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of O-6-methylguanine-DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis.
    Dahlrot RH; Dowsett J; Fosmark S; Malmström A; Henriksson R; Boldt H; de Stricker K; Sørensen MD; Poulsen HS; Lysiak M; Söderkvist P; Rosell J; Hansen S; Kristensen BW
    Neuropathol Appl Neurobiol; 2018 Feb; 44(2):172-184. PubMed ID: 28574607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequent MGMT (0(6)-methylguanine-DNA methyltransferase) hypermethylation in long-term survivors of glioblastoma: a single institution experience.
    Baur M; Preusser M; Piribauer M; Elandt K; Hassler M; Hudec M; Dittrich C; Marosi C
    Radiol Oncol; 2010 Jun; 44(2):113-20. PubMed ID: 22933901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of
    Lam K; Eldred BSC; Kevan B; Pianka S; Eldred BA; Zapanta Rinonos S; Yong WH; Liau LM; Nghiemphu PL; Cloughesy TF; Green RM; Lai A
    Neurooncol Adv; 2022; 4(1):vdac030. PubMed ID: 35386566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study.
    Costa BM; Caeiro C; Guimarães I; Martinho O; Jaraquemada T; Augusto I; Castro L; Osório L; Linhares P; Honavar M; Resende M; Braga F; Silva A; Pardal F; Amorim J; Nabiço R; Almeida R; Alegria C; Pires M; Pinheiro C; Carvalho E; Lopes JM; Costa P; Damasceno M; Reis RM
    Oncol Rep; 2010 Jun; 23(6):1655-62. PubMed ID: 20428822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.